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SUMMARY Acromegaly is a systemic syndrome caused by overproduc-
tion of growth hormone. The syndrome affects cutaneous, endocrine, 
cardiovascular, skeletal, and respiratory systems. Cutaneous manifes-
tations of acromegaly are various, usually being the first presenting 
findings of the disease. Forty-nine patients with acromegaly, followed-
up at a tertiary referral hospital, underwent dermatological examina-
tion. There were 27 (55.1%) female and 22 (44.9%) male patients. The 
age at onset of the disease was older in females than males (P=0.045). 
Most patients had acral enlargements, large triangular nose, coarse 
face, thickened lower lip, and prognathism. Fourteen (28.6%) patients 
had multiple cherry angiomas, five (10.2%) had varicose veins in lower 
limbs, and two (4.1%) had psoriasis. In conclusion, a wide spectrum of 
cutaneous symptoms and features may be associated with acromeg-
aly. Detailed dermatological examination of patients with acromegaly 
should be an essential component of systemic evaluation. Future pro-
spective studies investigating the relationships between changes in 
skin signs, hormone levels, and response to treatments may help un-
derstand details of skin involvement in acromegaly. 
KeY woRdS: acromegaly, cutaneous manifestations, multiple cherry 
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INTRodUCTIoN
Acromegaly is a systemic syndrome caused by 
overproduction of growth hormone (GH) in adult-
hood, after or around the time that the epiphyses 
close (1,2). The annual incidence of acromegaly is 
about 3-4 cases per million, with an estimated preva-
lence of 40 to 70 cases per million (3). The underlying 
pathology is pituitary adenoma in about 95% of pa-
tients. The diagnosis of acromegaly depends on the 
detection of high GH levels after oral glucose toler-
ance test (OGTT). After hormonal diagnosis, magnetic 
resonance imaging of the brain reveals the presence 
and size of adenoma and invasion to the adjacent 
tissues. Acromegaly affects both genders equally (4) 
and occurs most frequently in middle age. The mean 
age of diagnosis is 40 years in males and 45 years in 
females (5). The syndrome affects almost every organ 
system, mainly cutaneous, endocrine, cardiovascular, 
skeletal, and respiratory systems, due to increased 
levels of GH and insulin-like growth factor 1 (IGF1). 
High levels of GH and IGF1 are associated with high 
morbidity and mortality rates (6). Thus, early diagno-
sis is very important to initiate aggressive appropri-
ate treatments to lower these hormones. However, 
diagnosis of the disease is usually made with a delay 
of 7-10 years after the onset of symptoms (4,7). 
Cutaneous changes in acromegaly are classical 
features of the disorder, being an important clue for 
early diagnosis (2,8). Increased production of GH and 
IGF1 induces morphological alterations in skin mor-
phology. Oversecretion of IGF1 is stimulated by GH 
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and acts as the primary mediator of growth promot-
ing effects of GH (5). After binding to IGF1 receptors 
(IGFRs), proliferation and/or over-function of many 
cell lines such as keratinocytes, fibroblasts, pilar unit, 
Schwann cells, muscle cells, or medial and endothe-
lial cells of arteries are stimulated (2,8-11). Therefore, 
acromegaly presents with various cutaneous and 
systemic manifestations. Skin thickening and ede-
ma occur due to increased proliferation of keratino-
cytes and fibroblasts, accumulation and infiltration 
of glycosaminoglycan deposits (12). Besides these, 
periosteal new bone and cartilage formation causes 
increase in skeletal growth (13). Typical earliest and 
obvious manifestations involve skin and soft tissue, 
especially the face (marked facial lines, eyelid edema, 
large pores, widened and thickened nose, thick lips, 
prognathism, teeth separation, etc.) and extremities 
(hand and foot enlargement, heel pads, hard and 
thick nails) (5). 
Acromegaly may present with various cutaneous 
changes. Therefore, suspicion and careful evaluation 
of the skin findings of the disorder are very important 
(8). In this paper, dermatological symptoms and fea-
tures of patients with acromegaly who were followed-
up at a tertiary hospital are described and discussed 
through previously published reports.
PATIeNTS ANd MeTHodS
This was a cross-sectional study conducted pro-
spectively between February and August 2011 at a 
single tertiary referral hospital. A total of 49 patients 
who were on treatments in the outpatient endocri-
nology clinic were enrolled in the study. Of the pa-
tients, 33 were diagnosed in our endocrinology clinic 
and 16 were referred from other health centers for 
their maintenance therapies. All patients were diag-
nosed based on appropriate criteria for acromegaly 
and all had pituitary adenoma. Clinical findings along 
with (i) high IGF1 levels according to sex and age; (ii) 
random GH level >0.4µg/L; and (iii) no GH suppres-
sion (>1 µg/L) after OGTT indicated the diagnosis of 
acromegaly (4,14).
The symptoms and findings of dermatological 
and systemic examinations at the time of diagnosis 
were reviewed from the patient charts. Complete 
dermatological examination was performed for each 
patient at study entry. The estimated onset of acro-
megaly was calculated from age at presentation in 
years and duration of symptoms in years. The study 
was approved by the local ethics committee and con-
ducted according to the Declaration of Helsinki. All 
participants gave their written informed consent. 
Statistical analyses
Evaluation of normality was performed with the 
Kolmogorov-Smirnov test. Normally distributed con-
tinuous variables were expressed as mean and stan-
dard deviation (mean ± SD), and were compared with 
Student’s t-test. Non-normally distributed continu-
ous variables were expressed as median. P<0.05 was 
accepted to be statistically significant. All statistical 
analyses were performed using the SPSS version 17.0 
statistical software package (SPSS Inc., Chicago, Illi-
nois, USA).
ReSULTS
The study included 27 (55.1%) female and 22 
(44.9%) male patients, mean age 45.5±11.6 years (fe-
male: 49.4 ±10.4, male: 40.7 ±11.4) at study entry. The 
acromegaly symptoms were present for 8.7±5.6 years 
(range: 2 months-30 years). The mean estimated on-
set of acromegaly was 39.9± 12.5 years for females 
and 33.1±10.1 years for males. The age at onset was 
older in females than males (P=0.045). Duration of 
the disease was similar between female and male 
patients (P=0.281). Common presenting complaints 
in the patients were acral enlargements (71.4%), 
headache (40.8%), course face (22.4%), and hoarse-
ness (10.2%). Besides, some patients were diagnosed 
during evaluation for dysglycemia, amenorrhea, and 
thyroid disorders (Table 1). 
Dermatological findings of the patients are listed 
in Table 2. Most of the patients had acral enlarge-
ments, large triangular nose, coarse face, thickened 
lower lip, and prognathism on dermatological exami-
Table 1. Presenting complaints of patients with ac-
romegaly
Presenting complaints n %
Acral enlargements 35 71.4
Headache 20 40.8





Vision defects 3 6.1
Neurologic problem 2 4.1
Carpal tunnel syndrome 2 4.1
Amenorrhea 2 4.1
Thyroid disorder 2 4.1
Sleep apnea 2 4.1
Arthralgia 2 4.1
Galactorrhea 1 2.1
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nation. Cutis verticis gyrata was observed in 9 male 
and 3 female patients. Seborrheic keratoses (SK) were 
detected in 9 (18.4%) patients, age range 43-66 years. 
Hirsutism accompanied acromegaly in 4 female pa-
tients. All of them also had amenorrhea. Hypertricho-
sis over the non-androgen dependent areas of the 
body was seen in 8 male and 3 female patients. Five 
(10.2%) patients had varicose veins in lower limbs. Two 
patients had biopsy proven psoriasis, which emerged 
before acromegaly symptoms and partially regressed 
after the initiation of treatment for acromegaly. 
Of the study patients, 17 (34.5%) had hyperten-
sion, 11 (22.4%) diabetes mellitus, 6 (12.4%) impaired 
glucose tolerance, 23 (46.9%) thyroid disease includ-
ing multinodular goiter (n=17; 34.7%), hypothyroid-
ism (n=4; 8.2%), thyroiditis (n=2; 4.1%), and two 
(4.1%) had panhypopituitarism. Hypertension, dia-
betes mellitus, and thyroid disorders were more fre-
quent in females than males (P values, 0.028, 0.043, 
and 0.002, respectively). 
Surgical operations were performed in 48 patients. 
One patient could not undergo surgical treatment 
because of associated co-morbidities. Six patients un-
derwent conventional radiotherapy postoperatively. 
Medical therapy with somatostatin analogs was ad-
ministered to 45 patients. 
dISCUSSIoN
This study was conducted to analyze dermatolog-
ical features in a group of patients with acromegaly. 
We documented that the patients with acromegaly 
demonstrated various cutaneous signs although 
they were on therapies. In our study group, acral and 
facial changes were the most common presenting 
symptoms at admission and they were also the most 
common findings on our dermatological examina-
tions. These features were more frequent than in the 
series of 256 cases reported by Nabbaro (2). On the 
other hand, Arya et al. report on a recent study in 34 
patients with facial and acral involvement in all of 
them (15). 
Acrochordons in acromegalic patients have been 
reported in a wide range of 5.9% to 45% of cases 
(15-17). In the general population, acrochordons are 
usually associated with diabetes mellitus, insulin re-
sistance, and dyslipidemia (18). Hyperinsulinemia 
elevates free IGF-1 levels and stimulation of IGF1Rs 
induces epidermal hyperplasia (19). Although ac-
rochordons seem to be a component of metabolic 
complications of acromegaly, the association with 
colonic polyps still suggests a possible connection 
with acromegaly itself (18). Acanthosis nigricans is 
another cutaneous manifestation, which is not spe-
cific for acromegaly since it may accompany various 
metabolic and hormonal disturbances. In our study, 
the frequency of acanthosis nigricans was compara-
ble to previous large series (15,17). 
Detection of IGF1 immunoreactivity in the outer 
root sheath, hair matrix cells, sebaceous gland, ec-
crine sweat glands, and myoepithelial cells of the 
secretory portion of eccrine sweat glands (20) sug-
gests that hypertrichosis, oily skin, and hyperhidrosis 
are induced by high IGF1 levels in acromegaly. Hy-
perhidrosis is a common complaint of acromegalic 
patients with a frequency ranging between 50% and 
88% (2,21). It was observed almost in half of our pa-
tients. Since histology of the eccrine sweat glands in 
patients with acromegaly is similar with healthy con-
trols, hyperhidrosis seems to be related to hyperfunc-
tion of eccrine sweat glands rather than increased 
gland number (18). IGF1 was found to affect the 
Table 2. Cutaneous findings detected in patients 
with acromegaly
Cutaneous findings n %
Acral enlargements 43 87.8
Course face 43 87.8
Large triangular nose 40 81.6




Widened skin pores 33 67.3
Hyperhidrosis 25 51.0
Eyelid edema 24 49.0
Thickened heel pads 23 46.9
Oily skin 17 34.7
Thickened nails 14 28.6
Cherry angiomas 14 28.6
Cutis verticis gyrata 12 24.5
Hypertrichosis 11 22.4
Seborrheic keratoses 9 18.4
Acne 7 14.3
Acanthosis nigricans 7 14.3
Clubbing 5 10.2
Varicose veins 5 10.2
Hirsutism 4 8.2
Psoriasis 2 4.1
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human hair cycle by stimulating the growth of hair 
follicles potently and preventing them to enter the 
catagen phase (11). Although IGF/IGFR interaction 
seemed to be the main regulator of the pathogenesis 
of hirsutism and hypertrichosis of the patients, the 
interaction of IGF axis and androgens has not been 
investigated in detail. A small number of female acro-
megalic patients with hirsutism had normal levels of 
testosterone in the series of Nabarro (2). On the other 
hand, high IGF1 levels were found to be associated 
with adrenal hyperandrogenism in hirsute women 
without acromegaly (22). The authors suggested the 
role of IGF axis in the development of hirsutism. De-
tailed studies with a large number of acromegalic pa-
tients with hirsutism and hypertrichosis are needed 
to establish the association of high IGF1 levels and 
levels of androgens. 
Cutis verticis gyrata was one of the least frequent 
skin signs reported in the case series of acromegaly. 
It was not seen in the series of Arya et al. (15), and 
only 1.6% in the study by Nabbaro (2). In contrast, in 
our study, it was more frequently observed (24.5%) 
and was found to be more common in male acrome-
galic patients. Because of its subtle appearance under 
hairs, which prevents the lesion from being noticed 
by the patient or physician until it becomes obvious, 
the actual frequency of cutis verticis gyrata may be 
higher than reported. 
Beside typical cutaneous manifestations, multiple 
cherry angiomas (28.9%) and varicose veins (10.2%) 
were observed in our study group. These findings 
were not mentioned in previous series. Cherry angio-
mas are overgrowths of endothelial cells, categorized 
in vascular tumors. They are suggested to be a result 
of cutaneous angiogenesis with abnormal prolifera-
tion (23). The etiology and true prevalence of cherry 
angiomas are not well-known. Since 75% of adults 
were shown to have cherry angiomas, aging process 
has been suggested to have a role in the pathogen-
esis (24). In our study, most of the patients with cher-
ry angiomas were aged above 50. This may support 
the effect of aging; however, recent findings about 
the role of IGF1 in angiogenesis indicated the role of 
hormonal disturbances in acromegaly (25-27). The 
IGF1/IGF1R signaling pathway may induce cutaneous 
angiogenesis leading to the development of multiple 
cherry angiomas in patients with acromegaly. 
Varicose veins are a common venous disease 
of lower limbs in the general population. Reflux of 
blood in deep venous system due to incompetent 
valves and vein wall dilation are at the center of the 
pathophysiology of varicose vein formation. Matrix 
metalloproteinase (MMP) activation and fibrosis lead 
to vein wall damage (28). Varicose veins and relation-
ship with acromegaly have not been mentioned be-
fore. Since increased MMP levels have recently been 
demonstrated in acromegalic patients (29), vein wall 
damage due to MMP activation may be a trigger in 
varicose vein formation. 
Seborrheic keratosis is one of the most common 
skin tumors. The role of IGF in SK is not clear. Hodack 
et al. investigated IGFRs in 10 specimens of long 
standing and clinically non-enlarging SKs and failed 
to show overexpression of IGFRs in suprabasal layers 
(20). Stein et al. report on a patient with florid erup-
tion of SK associated with malignant tumor and high 
levels of IGF (30). The size and number of SK were de-
creased as IGF levels normalized. To date, SK has not 
Figure 1. Typical cutaneous manifestations of acro-
megaly in different patients: coarse face, large trian-
gular nose, and thickened lower lip (a); eyelid edema 
and prognathism (b); thickened heel pads (c); acral 
enlargement of hands (d).
Figure 2. Psoriasis plaques around the ankle of a pa-
tient with acromegaly.
Akoglu et al. Acta Dermatovenerol Croat
Acromegaly 2013;21(4):224-229
228 ACTA DERMATOVENEROLOGICA CROATICA
been noted in the cutaneous findings of acromegaly. 
Since it is frequent in general population, to mention 
this finding as a manifestation of the syndrome and 
to establish a true association with IGF levels in pa-
tients with acromegaly requires comparison studies 
with healthy individuals.  
IGF1 is one of the growth factors involved in the 
pathogenesis of psoriasis (31). It induces cell divi-
sion, proliferation of epidermal keratinocytes, and 
epidermal hyperplasia (32). Recently, El-Komy et al. 
demonstrated a significant increase in IGF1 mRNA 
in psoriatic plaques and reduction of its lesional lev-
els after treatment with methotrexate and psoralen 
plus ultraviolet A light therapies (33). Acromegalic 
patients with psoriasis have been reported to ben-
efit from pituitary tumor excision (34) or therapy with 
somatostatin analogs (35). In our series, two patients 
had psoriasis, which developed before the symptoms 
of acromegaly. The lesions regressed but not totally 
improved after the treatment for acromegaly. 
In our study, the present cutaneous manifestations 
of the patients were objectively defined. The major 
limitation of the present study was the unavailability 
to document the changes in cutaneous manifesta-
tions after the treatment periods and during their fol-
low-up because of its cross-sectional nature. In pre-
vious studies, it has been reported that several cuta-
neous manifestations of acromegaly might become 
stable or regress after successful inhibition of GH and 
IGF1 oversecretion (2,5). However, relationship be-
tween the change in cutaneous manifestations and 
response to therapies has not been fully investigated. 
Future prospective studies investigating the relation-
ship between changes in skin signs, hormone levels, 
and response to treatments may help understand de-
tails of the skin involvement in acromegaly. 
CoNCLUSIoN
We described cutaneous features of acromegaly 
in detail as well as some other findings that have not 
been reported before in acromegalic patients in the 
present study. Dermatological examination of pa-
tients with acromegaly is important as well as their 
systemic evaluation. Collaboration of dermatologists 
on acromegaly patient examination at their first ad-
mission and at regular visits is necessary for appropri-
ate and complete evaluation of these patients. 
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